Drug-Induced Hepatotoxicity

Have a question about this event?
Customer Service representatives are available to help from 8 AM - 6 PM EST
Call 888-670-8200

Need Technical Assistance With this Website?
Send an email to IIR's Web Department

Save the event dates in your Outlook calendar

Add to Outlook Diary

Advanced Search

Home»Events»Drug-Induced Hepatot...Event Overview

Drug-Induced Hepatotoxicity

The Only Industry, Academia & Government Event on Improving Techniques for Predicting Drug Induced Liver Injury Throughout the Entire Development Process

May 17 - 18, 2007 | Doubletree Hotel Washington DC

Event Overview

Online Documentation Now Available!

Updates on the Most Critical Issues!

Learn from your peers on how they identify toxicity in early stages
Achieve better predictions with the latest data comparing human studies and animal models
Uncover other co-factors that contribute to liver injury
Hear industry & academic insight into the benchmarks & limitations of new techniques
Explore lessons learned on post-marketing surveillance of hepatotoxic medications
Plus! The latest information on screening methods including:
     Gene Expression Profiling
     High Throughput In Vitro
     Toxicogenomics

From the Leading Research Specialists
Drug-Induced Hepatotoxicity promises to deliver content that brings together the most important components with cutting-edge presentations delivered from:

Academic Leaders

Industry Leaders

Robert Roth, PhD
Professor
MICHIGAN STATE UNIVERSITY

Debra Laskin, PhD
Professor & Chair, Department of Pharmacology & Toxicology
RUTGERS UNIVERSITY

Rich Miller, DVM, PhD, DACVP
VP, Safety Assessment
GLAXOSMITHKLINE & Conference Chair

William B. Mattes, PhD, DABT
Director of Toxicology,
THE CRITICAL PATH INSTITUTE

Michael D. DuVall, DVM, PhD
Group Leader Toxicology & Safety Pharm.,
Global Preclinical Safety,
ABBOTT LABORATORIES

Holly Jordan, DVM, PhD, Dipl ACVP
Director, Clinical Pathology
GLAXOSMITHKLINE

Yvonne Will, PhD
Group Leader: Molecular, Cellular & Biochemical Toxicology
PFIZER

Jeff Lawrence
Director of Biochemical Toxicology & Biomarkers
AMGEN

Christine Hunt, MD
Director of Global Hepatic Safety, Clinical Safety
GLAXOSMITHKLINE

Join us May 17-18, 2007 in Washington, DC as we cover the most pressing issues raised by your colleagues in the industry. This will be the most comprehensive and information - intensive event examining drug-induced hepatotoxicity yet!

Register Today!

A portion of the proceeds from this event will be donated to the American Liver Foundation (ALF). The ALF is the nation's leading nonprofit organization promoting liver health and disease prevention. ALF provides research, education and advocacy for those affected by liver-related diseases, including hepatitis. For more information about this organization, please visit www.liverfoundation.org